Literature DB >> 21484107

Evolution and management of de novo neoplasm post-liver transplantation: a 20-year experience from a single European centre.

Gonzalo Sapisochin1, Itxarone Bilbao, Cristina Dopazo, Luis Castells, Jose Luis Lázaro, Roberto Rodríguez, Mireia Caralt, Laia Blanco, Joaquin Balsells, Ramón Charco.   

Abstract

PURPOSE: Survival post-liver transplantation (LT) has improved; however, patients are considered at the, risk of malignancy due to prolonged immunosuppression. The long-term outcome of patients developing de novo neoplasm (DN) at our centre was evaluated.
METHODS: Between October 1988 and December 2007, 800 LT were performed in 742 patients. Patients were divided into two study periods according to the time of LT; first: October 1988-December 1995; second: January 1996-December 2007.
RESULTS: After a mean follow-up of 5 ± 4.6 years, 71 DN (9.5%) were detected in 742 patients. The cumulative risk of DN development increased with the time from LT although no differences at 3, 5, and 10 years were found when first and second periods were compared (3, 7, 16% vs. 2, 4, 11%, respectively; p = 0.4). DN incidence was higher in the first compared with the second period (10.7 vs. 7.8%; p < 0.04); no significant differences were observed in mortality rate (50 vs. 27%; p = 0.052). Actuarial patient survival post-DN at 1, 3, and 5 years: 67, 48, 45% versus 82, 71, 65%, in the first versus second period, respectively, p < 0.04.
CONCLUSIONS: DN incidence has decreased in recent years; however, as survival post-LT increases, so does the incidence of DN. Surveillance programmes are necessary to diagnose DN at early stages.

Entities:  

Year:  2010        PMID: 21484107      PMCID: PMC3090551          DOI: 10.1007/s12072-010-9231-1

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  34 in total

1.  Posttransplant malignancies.

Authors:  I Penn
Journal:  Transplant Proc       Date:  1999 Feb-Mar       Impact factor: 1.066

2.  Late mortality after orthotopic liver transplantation.

Authors:  J M Rabkin; V de La Melena; S L Orloff; C L Corless; H R Rosen; A J Olyaei
Journal:  Am J Surg       Date:  2001-05       Impact factor: 2.565

3.  Long-term survival after liver transplantation in 4,000 consecutive patients at a single center.

Authors:  A Jain; J Reyes; R Kashyap; S F Dodson; A J Demetris; K Ruppert; K Abu-Elmagd; W Marsh; J Madariaga; G Mazariegos; D Geller; C A Bonham; T Gayowski; T Cacciarelli; P Fontes; T E Starzl; J J Fung
Journal:  Ann Surg       Date:  2000-10       Impact factor: 12.969

Review 4.  Post-transplant de novo malignancies in renal transplant recipients: the past and present.

Authors:  H Myron Kauffman; Wida S Cherikh; Maureen A McBride; Yulin Cheng; Douglas W Hanto
Journal:  Transpl Int       Date:  2006-08       Impact factor: 3.782

5.  Risk factors for development of de novo neoplasia after liver transplantation.

Authors:  X Xiol; J Guardiola; S Menendez; C Lama; J Figueras; J Marcoval; T Serrano; J M Botargues; M Mañer; R Rota
Journal:  Liver Transpl       Date:  2001-11       Impact factor: 5.799

6.  Increased cancer risk after liver transplantation: a population-based study.

Authors:  E B Haagsma; V E Hagens; M Schaapveld; A P van den Berg; E G de Vries; I J Klompmaker; M J Slooff; P L Jansen
Journal:  J Hepatol       Date:  2001-01       Impact factor: 25.083

7.  Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy.

Authors:  Fu L Luan; Minoru Hojo; Mary Maluccio; Kouzaburo Yamaji; Manikkam Suthanthiran
Journal:  Transplantation       Date:  2002-05-27       Impact factor: 4.939

8.  [Characterization of de novo malignancies in liver transplantation].

Authors:  M V Catalina; A de Diego; A García-Sánchez; M Escudero; M Salcedo; R Bañares; G Clemente
Journal:  Gastroenterol Hepatol       Date:  2003-02       Impact factor: 2.102

9.  Risk factors associated with the development of skin cancer after liver transplantation.

Authors:  Abigail B Mithoefer; Stacey Supran; Richard B Freeman
Journal:  Liver Transpl       Date:  2002-10       Impact factor: 5.799

10.  Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma.

Authors:  Josep M Campistol; Alex Gutierrez-Dalmau; J Vicente Torregrosa
Journal:  Transplantation       Date:  2004-03-15       Impact factor: 4.939

View more
  6 in total

1.  De novo malignancy after liver transplantation: a single-center experience of 14 cases.

Authors:  Peng Ji Gao; Jie Gao; Zhao Li; Zhi Ping Hu; Ji Ye Zhu
Journal:  Ann Surg Treat Res       Date:  2015-03-26       Impact factor: 1.859

2.  Case report: Bone tumor of the scapula in a patient undergoing liver transplantation.

Authors:  Zhen-Qi Ding; Hai-Fang Zhang; Liang-Qi Kang; Mo Sha
Journal:  Clin Orthop Relat Res       Date:  2012-01-04       Impact factor: 4.176

3.  Dynamic tumor-tracking stereotactic body radiation therapy for a solitary tumor in a transplanted organ: two case reports.

Authors:  Shun Okabayashi; Yukinori Matsuo; Noriko Kishi; Hideki Hanazawa; Takashi Mizowaki
Journal:  Int Cancer Conf J       Date:  2020-06-29

4.  Analysis of adult 20-year survivors after liver transplantation.

Authors:  C Dopazo; I Bilbao; L L Castells; G Sapisochin; C Moreiras; I Campos-Varela; J Echeverri; M Caralt; J L Lázaro; R Charco
Journal:  Hepatol Int       Date:  2014-09-18       Impact factor: 6.047

5.  De novo cancers following liver transplantation: a single center experience in China.

Authors:  Songfeng Yu; Feng Gao; Jun Yu; Sheng Yan; Jian Wu; Min Zhang; Weilin Wang; Shusen Zheng
Journal:  PLoS One       Date:  2014-01-24       Impact factor: 3.240

6.  Pretransplant Hepatic Malignancy Increases Risk of De Novo Malignancy after Liver Transplantation.

Authors:  Gil Chun Park; Shin Hwang; Chul Soo Ahn; Ki Hun Kim; Deok Bog Moon; Tae Yong Ha; Gi Won Song; Dong Hwan Jung; Young In Yoon; Hui Dong Cho; Jae Hyun Kwon; Yong Kyu Chung; Sang Hyun Kang; Jin Uk Choi; I Ji Jung; Sung Gyu Lee
Journal:  J Korean Med Sci       Date:  2020-03-23       Impact factor: 2.153

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.